key: cord-0788937-17sv4j1z
authors: Cai, Changjing; Peng, Yinghui; Shen, Edward; Huang, Qiaoqiao; Chen, Yihong; Liu, Ping; Guo, Cao; Feng, Ziyang; Gao, Le; Zhang, Xiangyang; Gao, Yan; Liu, Yihan; Han, Ying; Zeng, Shan; Shen, Hong
title: A comprehensive analysis of the efficacy and safety of COVID-19 vaccines
date: 2021-08-06
journal: Mol Ther
DOI: 10.1016/j.ymthe.2021.08.001
sha: 8babeae719e41e1261dd3fa47c0ac6b5a1bbf05e
doc_id: 788937
cord_uid: 17sv4j1z

The numbers of cases and deaths from coronavirus disease 2019 (COVID-19) are continuously increasing. Many people are concerned about the efficacy and safety of the COVID-19 vaccines. We performed a comprehensive analysis of the published trials of COVID-19 vaccines and the real-world data from the Vaccine Adverse Event Reporting System. Globally, our research found that the efficacy of all vaccines exceeded 70%, and RNA-based vaccines had the highest efficacy of 94.29%; moreover, Black or African American people, young people and males may experience greater vaccine efficacy. The spectrum of vaccine-related adverse drug reactions (ADRs) is extremely broad, the most frequent ADRs are pain, fatigue and headache. Most ADRs are tolerable and are mainly grade 1 or 2 in severity. Some severe ADRs have been identified (thromboembolic events: 21-75 cases per million doses; myocarditis/pericarditis: 2-3 cases per million doses). In summary, vaccines are a powerful tool that can be used to control the COVID-19 pandemic, with high efficacy and tolerable ADRs. In addition, the spectrum of ADRs associated with the vaccines is broad, and most of the reactions appear within a week, while some may be delayed. Therefore, ADRs after vaccination need to be identified and addressed in a timely manner.

Introduction the analyses. The results showed that the most frequently reported ADR was pain (at 133 the injection site) after dose 1 in protein subunit vaccines (38.46%) and RNA-based 134 vaccines (80.97%). Pain was reported more frequently in younger vaccine recipients 135 (16 to 55 years old) than in older vaccine recipients (over 55 years old) (80.00% vs. 136 59.35%). Fatigue was the second most frequent ADR after dose 1 (30.77% of those 137 receiving the protein subunit vaccines and 39.27% of those receiving the RNA-based 138 vaccines). The incidence in the 16-to 55-year-old subgroup was significantly higher 139 than that in the over 55-year-old subgroup (52.72% vs. 33.73%). The incidences of 140 other ADRs were below 50%. Headache ranked third, followed by muscle pain 141 (myalgia), joint pain (arthralgia), chills, swelling, and fever. The incidence of ADRs 142 after vaccination with RNA-based vaccines was high, and further analysis of age 143 subgroups indicated that the results were generally consistent with those observed in 144 the overall analysis. Meanwhile, unlike the two vaccines above, in viral vector 145 (non-replicating) vaccines, the most frequently reported ADR was Fatigue (56.25%). 146 Headache ranked second, followed by pain, muscle pain (myalgia), joint pain 147 (arthralgia), chills, fever, and swelling. (Table 3 , Figure S3 -S5, Table S2) 148 149 Among participants who received dose 2, the overall incidence of ADRs was higher 150 than that after dose 1. As observed for dose 1, pain was the most frequent ADR. The and over 55 years old (51.06%). The incidences of ADRs other than pain differed 156 among the various types of vaccines. In particular, the incidence of ADRs was lowest 157 for inactivated vaccines, with incidences of all ADRs less than 10%. In descending 158 order of frequency, the ADRs were headache, swelling, fatigue, chills, joint pain 159 (arthralgia), muscle pain (myalgia), and fever. The ADRs associated with the other 160 three types of vaccines were similar to those after dose 1, with fatigue and headache 161 ranking second and third, respectively. However, more than 50% of recipients 162 experienced headache after dose 2, unlike after dose 1. Moreover, among the other 163 ADRs with incidences less than 50%, chills ranked fifth after dose 2, while it had 164 ranked sixth after dose 1, and the other ADRs in order were joint pain (arthralgia), 165 swelling, and fever. For RNA-based vaccines and viral vector (non-replicating) 166 vaccines, consistent results were obtained among subgroups stratified by age. (Table 3 , 167 Figure S7 -S10, Table S2 ) 168 169 To assess the severity of vaccine-related ADRs, we calculated the proportions (the 170 ADRs over grade 3 / all ADRs) and conducted a meta-analysis according to severity 171 grade. The results showed that the ADRs associated with the RNA-based vaccine 172 (MODERNA, BNT162b2) were the most severe, and instances of grade 3 reactions 173 were reported for all 8 ADRs. Fortunately, the proportions were low, and even the 174 largest was less than 20%. Grade 3 ADRs also occurred after vaccination with viral 175 vector (non-replicating) vaccines (AZD1222, Sputnik V); however, the proportions 176 J o u r n a l P r e -p r o o f were low (less than 10%). Most ADRs after vaccination with inactivated vaccines 177 (BBIBP) and protein subunit vaccines (NVX-COV2373) were grades 1-2. Importantly, 178 among the participants who received the first dose of an RNA-based vaccine, grade 4 179 fever was noted, but the proportion was less than 5%. Meanwhile, we also found that 180 younger participants were more likely to report higher-grade ADRs than older 181 participants. For the RNA-based vaccine (MODERNA) and protein subunit vaccine 182 (NVX-COV2373), the ADR grades were higher after the second dose than the first 183 dose. (Figure 1 , Table S2 ) 184 185 In the analysis of ADRs over grade 3, the incidences were all less than 10%, among 186 which the most frequently reported ADR was fatigue (6.34%) in RNA-based vaccines 187 after dose 2. The ADR grades were higher after the second dose than the first dose in 188 RNA-based vaccines, contrary to the viral vector (non-replicating) vaccines 189 (AZD1222, Sputnik V). What's more, the incidences of the ADRs over grade 3 in 190 viral vector (non-replicating) vaccines were higher than those in RNA-based vaccines 191 after dose 1. (Table 3, Figure S6 , S11, Table S2 ) 192 193 The severe and rare ADRs of COVID-19 vaccines 194 Besides the ones that have been reported in the clinical trials, there are some severe 195 and rare ADRs, such as thromboembolic events and myocarditis/pericarditis events, To evaluate the safety of the COVID-19 vaccines more comprehensively, we 209 retrospectively obtained real-world data pertaining to ADRs associated with 210 RNA-based vaccines from VAERS. A total of 11,936 participants were included in the 211 study, among whom 4990 were vaccinated with the MODERNA vaccine and 6946 212 were vaccinated with the PFIZER-BIONTECH vaccine. (Table S4) 213 214 Our research revealed an unexpected phenomenon. The incidence of ADRs in the real 215 world was far lower than that in clinical trials. The ADR with the highest incidence is 216 headache (16.53%), but the spectrum of ADRs is significantly wider than that in 217 clinical trials. We identified more than 700 ADRs, but the incidence of most ADRs 218 (more than 90%) was lower than 1%. ( Figure 3D ) To evaluate the tolerance of the 219 vaccine in different populations, we conducted subgroup analyses stratified by age, 220 J o u r n a l P r e -p r o o f sex, and vaccine manufacturer. All ADRs with incidences higher than 5% were 221 included. After stratification by the vaccine manufacturer (MODERNA and 222 PFIZER-BIONTECH), the results showed that there were no significant differences in 223 the incidences of headache, pain, myalgia, and nausea, but the incidences of chills, Table   230 S6. Headache was still the most frequent ADR after the subgroup analysis was Table S7 and Table S8 . In the analysis stratified by 236 sex, we found that regardless of whether the MODERNA or PFIZER-BIONTECH 237 vaccine was administered, pyrexia ranked first, which was different from the results 238 of the other subgroup analyses. Other than pyrexia and chills, which were more 239 common in males, the incidences of other ADRs were higher in females than in males. Table S9 and Table S10 . 

Most symptoms appear soon after vaccination, and many people recover without any 279 medication.

In terms of efficacy, RNA-based vaccines ranked first, reaching greater than 94%, due 282 to their strong immunogenicity and effective presentation of SARS-CoV-2 antigens to 283 the immune system 7 . Currently, mutant virus strains are also attracting attention.

RNA-based vaccines may be more effective against these mutant strains owing to 285 their use of the full immunogenicity of SARS-CoV-2. However, the incidence of 286 J o u r n a l P r e -p r o o f ADRs is high after vaccination with RNA-based vaccines, reaching over 80% based 287 on the clinical trial data, with the incidences of grade 3 or 4 ADRs accounting for a 288 small proportion. Although the real-world incidence of ADRs was lower than that in 289 the clinical trials, the spectrum was broader, and a large portion of types of ADRs 290 were not observed in clinical trials, suggesting that attention should be given to the 291 identification and treatment of rare ADRs. Meanwhile, myocarditis/pericarditis have 292 been identified in RNA-based vaccines; fortunately, the incidence was low. Protein 293 subunit vaccines had an efficacy of 89%, while the highest incidence of ADRs was 294 only 57%, and highest incidence of the ADRs over grade 3 was 3.85%, significantly 295 lower than that associated with RNA-based vaccines; therefore, it may be a promising 296 candidate. However, real-world data regarding protein subunit vaccines are lacking 297 and the sample of published data is small, further analysis is needed. Moreover, viral 298 vector (non-replicating) vaccines have an efficacy of 79%, while the highest incidence 299 of ADRs is 40%. In addition, the incidence of ADRs above grade 3 is significantly 300 lower than that associated with RNA-based vaccines. However, some vaccines is gradual in vaccinated recipients. We also found that young people seem to 318 be relatively more prone to higher grade ADRs. We speculate that the relatively 319 stronger immune systems in young people lead to both a higher incidence of ADRs 320 and greater vaccine efficacy 8 . This finding also reduces concerns about vaccinating 321 elderly people. The higher incidence of ADRs among female participants than male 322 participants is puzzling, because it suggests that a stronger immune response were 323 elicited in females, but the efficacy is lower in females than in males. This is 324 inconsistent with the results of previous studies on sex differences 9 . The specific 325 reasons need to be explored further. Furthermore, in the analysis of the timing of the 326 onset of ADRs, we found that young people and females developed symptoms earlier, 327 which may be related to the higher incidence of ADRs and their stronger immune In the ADR analysis, the real-world data from the VAERS and clinical trial data were 334 compared. We found that there are differences in the spectrum of ADRs, with a wider 335 spectrum of ADRs identified in the real-world data. One plausible explanation is that 336 the data in VAERS are continuously and openly collected. However, only ADRs that 337 occurred within one week were counted in most clinical trials, and those that appeared 338 after one week were omitted. In addition, the VAERS system lacks a standardized 339 description of symptoms, with multiple different descriptions referring to the same 340 ADR, falsely increasing the spectrum of ADRs. Another surprising finding is that the 341 incidence of ADRs in the real world is far lower than that in clinical trials. Real-world 342 data is only available for RNA-based vaccines, and the sample size is not yet large 343 enough. Additionally, the VAERS is a self-reporting system with reporting bias 10 , and 344 a large number of participants who were vaccinated did not report their ADRs, 345 resulting in a lower incidence rate than in clinical trials.

We also found that few cases of mortality were reported to VAERS, and there was not 348 enough evidence to indicate that the death was related to vaccination after carefully 349 assessing each case. Therefore, a large-scale real-world study is needed for further In addition, we also conducted sensitivity analyses and multiple subgroup analyses to 358 minimize heterogeneity. Both fixed-effect model and random-effect model were 359 performed. When I 2 was less than 50% and P>0.1, the fixed-effect model was chosen; 360 otherwise, the random-effect model was chosen 12-14 .

The Begg's and Egger's tests were not used because there were not more than 10 363 subjects in each group 15 . Although some subgroups were heterogeneous, we 364 determined that the heterogeneity was derived from the data itself after sufficient 365 statistical correction and analysis, possibly due to factors such as the area in which the 366 study was conducted, the risk of exposure to SARS-CoV-2, and other factors that All 291,000,0 results initially identified studies were screened; those that were clinical 421 trials (n= 1), cohort study (n= 3)，case reports(n=12), and official reports (n=8) were 422 included. Those study that without the data of exact total number and exact number of 423 patients with thromboembolic or myocarditis or pericarditis were excluded (n=14).

Those official reports that outdated or without the data of exact vaccine type (n=3) 425 were excluded. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f Figure S2 . Forest plot of the efficacy of COVID-19 vaccine. Meta-analysis was performed using R statistical software. Event rates and their corresponding 95% confidence intervals were estimated using both a fixed-effects model and a random-effects model. (A) vaccine group stratified by vaccine type (B) placebo group stratified by vaccine type (C) vaccine group stratified by age (D) placebo group stratified by age (E) vaccine group stratified by gender (F) placebo group stratified by gender (G) vaccine group stratified by race (H) placebo group stratified by race. Figure S3 . Forest plot of the incidence of ADRs after dose 1 (subgroups by vaccine type). Meta-analysis was performed using R statistical software. Event rates and their corresponding 95% confidence intervals were estimated using both a fixed-effects model and a random-effects model. Figure S4 . Forest plot of the incidence of ADRs after dose 1 (subgroups by age). Meta-analysis was performed using R statistical software. Event rates and their corresponding 95% confidence intervals were estimated using both a fixed-effects model and a random-effects model. 

Heterogeneity: I 2 = 97%, τ 2 = 0.2623, p < 0.01 Residual heterogeneity: I 2 = 97%, p < 0.01 subgroup = RNA based vaccine subgroup = viral vector

Heterogeneity: I 2 = 98%, τ 2 = 0.2883

Heterogeneity: I 2 = 26%, τ 2 = 0.0069